
New MGA Paper Identifies Barriers to US Biosimilar Success in the Second Decade
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
Alex Brill and Christy Robinson look at the US biosimilars market a decade after the first biosimilar approval.
The Food and Drug Administration (FDA) has approved a record number of biosimilars in 2024, and the year is only half over.
Fourteen years ago, Congress established a regulatory pathway for biosimilars, direct competitors to branded biologic drugs.
Insulin, a drug first developed more than 100 years ago, has experienced a surge in political interest in recent years following dramatic price hikes.
Alex Brill recently joined the GRx+Biosims 2023 conference panel to discuss biosimilars and the keys to success in the pharmacy benefit.